Following the encouraging initial results of the pilot project, the Ministry of Health is committed to increasing access to MDR-TB diagnosis, treatment and care. An expansion plan for the programmatic management of drug-resistant ...ute-to-highlight medbox">TB has been developed and forms part of the Five Year National Strategic Plan for TB Control, 2011-2015. The long-term goals of the MDR-TB expansion plan are threefold:
1. Diagnosis of MDR-TB in all groups of patients at risk for MDR-TB
2. Diagnosis of MDR-TB in all HIV-infected TB patients
3. MDR-TB treatment for all patients diagnosed with MDR-TB under WHO-endorsed treatment protocols
more
National Tuberculosis Control Program; Mycobacterial Disease Control National AIDS/STD Program
Specific measures are being taken within the National Tuberculosis Control Programme (NTP) to address the MDR TB problem through appropriate management of patients and strategies to prevent the propagation and dissemination of MDR ...bute-to-highlight medbox">TB.
The term "Programmatic Management of Drug Resistant TB" (PMDT) refers to programme based MDR TB diagnosis, management and treatment. This guideline promotes full integration of basic TB control and PMDT activities under the NTP, so that patients with TB are evaluated for drug resistance and are placed on the appropriate treatment regimen and properly managed from the outset of treatment, or as early as possible. The guidelines also integrate the identification and treatment of more severe forms of drug resistance, such as extensively drug resistant TB (XDR TB).
At the end, the guideline introduces new standards for registering, monitoring and reporting outcomes of multidrug resistant TB cases.
more
A large meta-analysis of observational studies that provided the basis for the recent makeover of global recommendations for multidrug-resistant tuberculosis (MDR-TB) treatment shows that newer and repurposed drugs produced better outcomes and fewer... deaths than older treatments.
The meta-analysis of 50 studies involving 12,000 patients from 25 countries, published yesterday in The Lancet, found that bedaquiline, linezolid, levofloxacin, and moxifloxacin were associated with greater treatment success and reduced mortality compared with the previously recommended first-line treatments, while clofazimine and carbapenem antibiotics were associated with significantly improved treatment outcomes (but not reduced mortality)
more
Информация о туберкулезной терапии для больных и их родственников.
Информация о диагностике туберкулеза для больных и их родственников.
Информация о туберкулезной терапии для больных и их родственников
Данный информационный листок является второй частью предыдущего информационного листка о туберкулезе (ТБ). Он содержит подробную информацию об особой форме т...уберкулеза, известной под названием туберкулез с множественной лекарственной устойчивостью (ТБ-МЛУ). Оба информационных листка опубликованы в рамках проекта «TB PAN-NET».
Accessed on September 2019
more
Лечить пациента, а не болезнь: ориентированный на человека подход
7й симпозиум по вопросам лечения туберкулеза - презентация
Accessed: 08.10.2019
Based on the National Guidelines for the Management of Tuberculosis in Children 2013, Department of Health, South Africa.
План предназначен как методическое руководство для наиболее приоритетных стран Региона при разработке собственных долго- и краткосрочных национальных планов в о...тношении ТБ, а также послужит руководством к действию для Европейского регионального бюро ВОЗ и всех других партнеров по борьбе с ТБ.
more
Презентация модели лечения ЛУ-ТБ в Житомирской области
Consolidated Guidelines
Geneva, 2016
The End TB Strategy
Dans la plupart des pays, les services de lutte contre la tuberculose (TB) sont décentralisés jusqu’aux dispensaires
les plus périphériques et souvent au sein même des villages et des quartiers. Par contre, les services
de lutte contre le V...IH/Sida sont généralement beaucoup plus centralisés parce que la diffusion des
soins, notamment de la thérapie antirétrovirale (TARV), n’a commencé qu’assez récemment. De ce fait,
les patients qui ont besoin d’un traitement à la fois contre la tuberculose et le VIH/Sida peuvent être obligés
de se rendre dans deux établissements distincts et ainsi d’avoir à parcourir de longues distances pour
accéder aux soins. L’absence de services intégrés TB/VIH peut provoquer des retards dans le diagnostic
et le traitement, et même se traduire par un mauvais suivi des traitements, voire par des interruptions. Par
ailleurs, les patients ont à supporter la charge financière des frais de déplacement et des autres coûts indirects,
tels que de longs temps d’attente et une perte de revenu
more
Policy and service delivery guidelines for linkage to care, adherence to treatment and retention in care
February 2016
Integrated Management of Adolescent and Adult Illness (IMAI)
July 2008
Accessed: 10.03.2020
Treatment Action Campaign (TAC):
Working for Access to quality Public Healthcare in South Africa since 1998
Updated 24 March 2020 (24 Maart 2020)